Trial Profile
A Randomized, Multicenter, Phase II Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-Expressing Inflammatory Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Lapatinib
- Indications Inflammatory breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 17 Jul 2012 Actual number of patients changed from 184 to 163, as reported by ClinicalTrials.gov.
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.